Announcements

Up to 20% of women and 10% of men suffer from mental health problems during pregnancy and in the first year after the birth of the child. Due to the potentially severe impact on parents and child, there is an urgent need for rapid and effective care. This scoping review provides an overview of international models for the prevention and care of perinatal mental health problems and describes their similarities and differences. The review is part of the FWF funded research project ‘Co-designing perinatal mental health support in Tyrol’.

QRs in dementia care are systems to support decision-makers and healthcare planners in developing optimal dementia care pathways while improving the quality of dementia care services and patient outcomes. The aim of the report was to analyse dementia QRs and to provide an overview of the quality indicators used including the underlying evidence. In addition, the empirical results from the identified dementia QRs, in combination with good registry practice from the literature, were embedded into a good practice framework.

Mental disorders in children and adolescents are among the most common illnesses with a high burden of disease. The increasing need for care with simultaneous bottlenecks in health services leads to considerations for other care and prevention models. In this context, in this research report international models for prevention and care for child and adolescent mental health were analysed. In addition, an overview of relevant indicators specifically for this population was compiled. Based on these international recommendations, possibilities for the further development of the current Austrian care structures were identified.

The two CAR-T cell therapies Kymriah^® and Yescarta^® were approved by the EMA in 2018 for patients with B-cell acute lymphoblastic leukaemia (B-ALL), diffuse large B-cell lymphoma (DLBCL) or primary mediastinal B-cell lymphoma (PMBCL) in third line. Treatment is often associated with high expectations, but the evidence on efficacy and safety of these novel therapies is still uncertain. The aim of this systematic review was to contrast the results of patient characteristics as well as selected efficacy and safety endpoints from the pivotal trials with those from real-world evidence studies. In addition, the results and conclusions of other HTA reports were summarised regarding the available evidence on efficacy and safety.